Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | TNKS | O95271 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4700239 | 1.00 | ALDH1A1 (0.41) | ALDH1A1TDP1TNKSTSHRSMN1; SMN2 | |
| SCHEMBL4700241 | 1.00 | ALDH1A1 (0.41) | ALDH1A1TDP1TNKSTSHRSMN1; SMN2 | |
| SCHEMBL14103254 | 1.00 | ALDH1A1 (0.41) | ALDH1A1TDP1TNKSTSHRSMN1; SMN2 | |
| SCHEMBL13046376 | 0.80 | TNKS (0.49) | ALDH1A1TDP1TNKSTSHRSMN1; SMN2 | |
| SCHEMBL30209937 | 0.80 | TNKS (0.49) | ALDH1A1TDP1TNKSTSHRSMN1; SMN2 | |
| SCHEMBL30210235 | 0.76 | TNKS (0.49) | ALDH1A1TDP1TNKSTSHRSMN1; SMN2 | |
| SCHEMBL3186527 | 0.76 | USP2 (0.57) | ALDH1A1TDP1TSHRSMN1; SMN2HTT | |
| SCHEMBL3181073 | 0.76 | USP2 (0.57) | ALDH1A1TDP1TSHRSMN1; SMN2HTT | |
| SCHEMBL3181082 | 0.76 | USP2 (0.57) | ALDH1A1TDP1TSHRSMN1; SMN2HTT | |
| SCHEMBL13045932 | 0.73 | ALDH1A1 (0.50) | ALDH1A1TNKSSMN1; SMN2HTTCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1467979-B1 | FUSED HETEROCYCLIC COMPOUNDS AND ANALOGS THEREOF MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2008-08-13 | — | — | EP | claimed |
| US-7087636-B2 | Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-08-08 | — | — | US | claimed |
| US-20030181728-A1 | Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-25 | — | — | US | claimed |
| EP-1467979-B1 | FUSED HETEROCYCLIC COMPOUNDS AND ANALOGS THEREOF MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2008-08-13 | — | — | EP | disclosed |
| US-7342034-B2 | Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-11 | — | — | US | disclosed |
| US-7291637-B2 | Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| US-7087636-B2 | Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-08-08 | — | — | US | disclosed |
| US-20060020002-A1 | Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function | SALVATI MARK E | 2006-01-26 | — | — | US | disclosed |
| US-20050187273-A1 | Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function | SALVATI MARK E (US) | 2005-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020002-A1 | Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, NR5A2, NR5A1 | ALDH1A1 3872/4885TDP1 4098/4885TNKS 2956/4885 |
| US-20050187273-A1 | Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, NR5A2, NR5A1 | ALDH1A1 3872/4885TDP1 4098/4885TNKS 2956/4885 |
| US-20030181728-A1 | Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, NR5A2, NR5A1 | ALDH1A1 3872/4885TDP1 4098/4885TNKS 2956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.